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a b s t r a c t 
Liver metastasis from breast cancer is associated with poor prognosis and is a major cause 
of early morbidity and mortality. When liver resection is not feasible, minimally invasive di- 
rected therapies are considered to attempt to prolong survival. Selective internal radiation 
therapy (SIRT) with yttrium-90 microspheres is a liver-directed therapy that can improve 
local control of liver metastases from colorectal cancer. We present a case of a patient with 
a ductal breast adenocarcinoma, who developed liver and bone metastasis despite exten- 
sive treatment with systemic chemotherapies. Following SIRT to the liver, after an initial 
response, the patient ultimately progressed in the liver after 7 months. Liver tumor his- 
tology obtained 20 months after the SIRT intervention demonstrated the presence of the 
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resin microspheres in situ. This case report demonstrates the long-term control that may 
be achieved with SIRT to treat liver metastases from breast cancer that is refractory to pre- 
vious chemotherapies, and the presence of microspheres in situ long-term. 
© 2018 The Authors. Published by Elsevier Inc. on behalf of University of Washington. 
This is an open access article under the CC BY-NC-ND license. 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Background 
Breast cancer is a leading cause of mortality worldwide [1] . It
represents a heterogeneous group of subtypes with charac-
teristic molecular features, prognosis, and responses to treat-
ment [2] . The development of liver metastasis from breast
cancer heralds a poor prognosis [3] . If it is feasible, hepatic re-
section is of offered to patients, but unfortunately the vast ma-
jority are unresectable at the time of diagnosis of liver metas-
tasis [3] . Other liver-directed therapies have been attempted
for liver-only disease with the primary aim of palliating and
prolonging survival. These treatments include radiofrequency
[4,5] and microwave ablation, transarterial chemoemboliza-
tion [6] , selective internal radiation therapy (SIRT) [7] , and
stereotactic body radiotherapy [8,9] . 
SIRT was developed as a liver-directed therapy for
metastatic colorectal cancer and primary liver cancer [10] .
Recently, a randomized multicenter clinical trial has demon-
strated an improvement in radiological response rate and hep-
atic progression-free survival in patients with metastatic col-
orectal cancer treated with SIRT [11] . In case reports and small
case series, SIRT has also been used to treat liver metastases
from other primary tumors including breast [12] , neuroen-
docrine [13] , and pancreas [14] . 
SIRT involves the administration of yttrium-90 ( 90 Y) mi-
crospheres via the arterial blood supply of liver metastases
[15] . The microspheres are typically about 30 μm in diameter.
The administered dose is targeted by meticulous angiography
of the tumor and its vasculature. Potential adverse events of
SIRT therapy include postradioembolization syndrome (PRS)
(20%-55% of patients), radioembolization-induced liver dis-
ease (REILD), damage to the biliary system including radia-
tion cholecystitis, portal hypertension, radiation pneumonitis,
gastroduodenal ulceration, vascular injury, and lymphopenia
[10,16,17] . PRS typically consists of mild fatigue, gastrointesti-
nal upset, anorexia, fever, and cachexia and it may require
symptomatic management. REILD is defined as jaundice and
ascites 1 to 2 months after a radioembolization procedure, in
the absence of tumor progression or bile duct occlusion [18] .
One prospective study evaluated 45 patients without chronic
liver disease who underwent radioembolization for the liver in
a single institution and 9 (20%) went on to develop REILD in the
first 90 days [19] . All these patients had received chemother-
apy preprocedure or postprocedure and population analysis
strongly suggested that the syndrome associated with the
combined effect of radiation and chemotherapy. 
There are some reports of tumur pathology from hepatic
resection after SIRT, all of which focus on colorectal liver
metastases [20–22] . In colorectal patients, microspheres have
been identified in the vascular tumor bed and the portal tract
vessels within liver parenchyma following SIRT [20] . Thesemicrospheres were typically associated with giant cell re-
action or histiocytes. In the tumor bed, the blood vessels
and fibroblasts showed changes suggestive of radiation injury.
Necrosis, mucin and calcification have also been described.
Another study describes a patient with metastatic cholangio-
carcinoma, who had a partial response to SIRT and went on
to a liver resection and remained disease-free at 9 months
[22] . Histology demonstrated residual microspheres with ev-
idence of moderate-to-severe hepatic inflammation and early
stage fibrosis, with 50% overall tumor necrosis. In the same
study, a patient with metastatic rectal cancer also went on to
have a liver resection, and this time histology revealed resid-
ual microspheres, moderate-to-severe inflammation with no
evidence of fibrosis and 80% tumor necrosis. In addition, the
study describes residual microsphere embolization surround-
ing resected esophageal and cholangiocarcinoma liver metas-
tases with 80% and 45% tumor necrosis, respectively. Another
study examined the histology of the nonneoplasic liver in 7
patients 6-23 months following SIRT in metastatic colorectal
cancer [3] , hepatocellular carcinoma [2] , and neuroendocrine
tumor [1,23] . Of the 7 tissue samples, 6 were core biopsies and
1 was a wedge resection. Of the biopsies, 5/6 demonstrated mi-
crospheres, typically in the portal tracts, and without signifi-
cant associated inflammation. Mild portal vein dilatation was
seen in 3/6, mild portal fibrosis in 2/6, and in 1 case a particle
was demonstrated in an artery with associated thrombus. The
wedge resection demonstrated extensive coagulative necro-
sis of hepatocytes due to portal vein thrombosis. The study
suggests that SIRT causes little diagnostic pathologic change
in the normal liver surrounding the liver metastasis, and that
the microspheres are generally found in the portal tracts with
little inflammatory reaction. 
Publications of long-term outcomes, including histology,
in breast cancer patients with liver metastases who have re-
ceived SIRT are currently lacking, so it is not known what his-
tological changes are observed in breast cancer metastases.
This report describes radiological outcomes and histology in
an extensively pretreated breast cancer patient who under-
went tumor biopsies 20 months after receiving SIRT. It rep-
resents the first report of tumor histology so long after SIRT
in a patient with metastatic breast cancer, demonstrating the
presence of microspheres distributed in the stroma surround-
ing viable tumor. 
Clinical presentation 
Written informed consent was obtained from the patient for
publication of this case report, including accompanying im-
ages. A 49-year-old woman, with no past medical history
of note, presented with right-sided grade 2, node positive,
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 estrogen-receptor (ER) positive breast cancer in 1996. She
received 6 cycles of neoadjuvant cyclophosphamide, epiru-
bicin, fluorouracil prior to resection, after which she was
commenced on adjuvant cyclophosphamide, methotrexate, 5-
fluorouracil . A 3.4 cm grade 2 ER-positive tumor was resected,
and 6/8 lymph nodes were positive. She received a course of
adjuvant tamoxifen over a period of 4 years, which was then
stopped due to menorrhagia. Five years’ post diagnosis, the
patient relapsed with a new 1 cm, grade 2, left-sided primary
breast tumor, which was ER- and progesterone-receptor (PR)
positive, lymph node negative. She received surgery, radiother-
apy, and adjuvant letrozole, which was completed in 2006. 
There was relapse in 2010 with a solitary bone metas-
tasis in the pubic ramus of the right hemipelvis, but no
evidence of soft tissue disease elsewhere. Exemestane was
commenced, with a single fraction of 8 Gy palliative radio-
therapy to the affected area. The cancer antigen (CA 15-3) bio-
chemical marker was elevated at 121 U/mL at this stage, but
fell on this therapy. Two liver metastases developed in Novem-
ber 2011, the largest of which was 17 mm, and at this stage
exemestane was replaced with a further course of tamoxifen
and alendronic acid was also commenced. The liver metasta-
sis initially remained stable on this treatment. A year later, the
serum CA 15-3 marker had demonstrated gradual increases
up to the low 300s and the patient was given radiotherapy to
right hip. Fulvestrant hormonal therapy was started, which
initially reduced the serum CA 15-3. However, liver disease
was progressive in 2012 and fulvestrant was replaced with
capecitabine. Liver disease continued to progress in 2013, con-
sequently capecitabine was stopped and she was referred for
consideration of SIRT, which was recommended by multidis-
ciplinary team meeting discussion. 
Treatment 
The SIRT procedure to the liver was performed in Oxford, UK
in September 2013. The pre-SIRT procedure utilized a right
femoral approach to perform coil embolization at the origin
of the main gastroduodenal trunk, the first branch of the left
hepatic artery and the right gastric artery allowing isolation of
the right gastric territory. The SIRT procedure itself involved
a further coil embolization to the segment IV vessel to al-
low more distal delivery of Y90 SIR-spheres in the right hep-
atic circulation. During the SIRT procedure, 1100 megabec-
querel (MBq) was delivered in a split dose, 800 MBq to right
hepatic artery, and 300 MBq to left hepatic artery. A single-
photon emission computed tomography (CT) scan was per-
formed 18 hours post-SIRT procedure; distribution of radioac-
tivity within and around the liver metastases was demon-
strated ( Fig. 1 ). 
Outcome and follow-up 
Follow-up magnetic resonance imaging (MRI) 11 weeks after
SIRT revealed a partial response of liver metastases, and MRI
analysis using specialist 3D volumetric software (Advantage
Workstation Volume Share v2) showed that the liver volume
was 1184 cm 3 of which 39 cm 3 was metastatic tumor bur-den (3.3% hepatic replacement). This was compared to a pre-
SIRT liver volume of 1401 mL on baseline MRI, of which 208
mL was metastatic tumor (14.8% hepatic replacement). The
follow-up MRI also demonstrated new vertebral bony metas-
tasis in the cervical, thoracic, and lumbar spine and deno-
sumab and megace were started. Further radiological follow-
up of liver metastases with MRI demonstrated stable disease
at 4 months, after which there was disease progression at 7
months ( Fig. 2 ). 
Megace was discontinued in April 2014 due to disease pro-
gression and oral vinorelbine commenced. The patient con-
tinued to progress on subsequent scans, demonstrating ag-
gressive liver disease with a markedly elevated CA 15-3 tu-
mor marker at this stage, and consequently the patient was
referred for early-phase clinical studies. Twenty months fol-
lowing the SIRT procedure, 3, 18-guage core biopsies of a
liver metastasis within the segments previously treated with
SIRT were obtained under ultrasound-guidance as part of
an ethically approved clinical study in targeted drug deliv-
ery [24,25] . Sections of these biopsies were formalin-fixed,
paraffin-embedded for subsequent microscopic analysis. Rou-
tine hematoxylin and eosin staining was performed and
demonstrated tumor, consistent with breast cancer, set in fi-
brous stroma ( Fig. 3 ). One of 3 available biopsy specimens re-
vealed the presence of 6 resin microspheres, which were not
associated with a surrounding macrophage response. All biop-
sies were taken from the core of the target tumor and no con-
trol biopsies were taken, thus it was not possible to assess the
tumor bed or surrounding normal liver architecture for radia-
tion damage or other background liver disease such as steato-
hepatitis. 
Discussion 
Several retrospective studies have explored the use of SIRT in
chemorefractory metastatic breast cancer to the liver. In 2007,
Bangash et al demonstrated a complete or partial response at
90 days in 9/27 women with progressive breast cancer who
had failed standard of care chemotherapy, whilst 2/27 pro-
gressed and the remainder were stable [26] . The same year
Coldwell et al published series of 44 heavily pretreated women
with breast liver metastasis, showing a 47% partial response
rate by CT at 12 weeks, and higher response rate by PET [27] . In
2008, Jakob et al published a study which demonstrated par-
tial response in 61% in 23 women with at a median follow-up
of 4.2 months with a median overall survival of 11.7 months,
23.6 months in the responding group vs 5.7 months in non-
responding group [28] . In 2012, Haug et al demonstrated a
similar median overall survival of 47 weeks in 58 women re-
ceiving SIRT for breast liver metastasis [12] . Further following
2-[ 18 F]-fluoro-2-deoxy- d -glucose positron emission tomogra-
phy/computed tomography analysis, SUV max correlated sig-
nificantly with survival, and indeed the change in its value
3 months’ post-SIRT was the only independent predictor of
survival. At around the same time, Cianni et al demonstrated
similar outcomes with a median overall survival of 11.5 with
a 56% partial response in 52 breast cancer patients receiving
liver-directed SIRT [29] . In the largest study of SIRT in breast
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Fig. 1 – Radiological imaging obtained from the patient treated with SIRT in 2013. Top: Fluoroscopy performed during (left) 
and immediately following injection of yttrium-90 resin microspheres (right), the later image showing blush of radioopacity 
predominantly overlying the right side of liver. Bottom left: Fat saturation MRI in axial section obtained 9 days prior to SIRT, 
with the white arrow demonstrating the location of the tumor subsequently biopsied in an early phase cancer study in 
2015. Bottom right: Post-SIRT SPECT-CT scan at a similar axial section demonstrating high doses of radioactivity in 
segments V and VI of the liver coregistering the tumor distribution. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 cancer patients to date, Gordon et al showed a partial response
of 35.3% and stable disease in 63.2%, with a median overall
survival of 6.6 months in 75 patients [30] . 
One systematic review included 6 retrospective cohort
studies in which SIRT was used to treat breast cancer liver
metastases, including 198 patients overall [31] . The study con-
cluded that SIRT is well tolerated and effective for this pa-
tient cohort with end-stage disease and a high tumor burden.
Gastric ulceration was seen in 5% of patients and treatment-
related mortality in 2% thought due to radiation-induced liver
disease. In these retrospective cohorts, disease control (com-
plete response, partial response or stable disease) was seen in
78%-96% at 2-4 months. Prospective data in this patient cohort
are currently lacking. 
There are some reports of tumor histopathology from
hepatic resection after SIRT, all of which focus on colorectal
liver metastases [20–22] . In colorectal patients, microspheres
have been identified in the vascular tumor bed and the portal
tract vessels within liver parenchyma following SIRT [20] .These microspheres were typically associated with giant cell
reaction or macrophages, a feature not seen in the case of
the breast tumor histology presented here. In the tumor bed,
the blood vessels and fibroblasts showed changes suggestive
of radiation injury. Necrosis, mucin, and calcification have
also been described. Another study describes a patient with
metastatic cholangiocarcinoma who had a partial response to
SIRT and went on to a liver resection and remained disease-
free at 9 months [22] . Histology demonstrated residual
microspheres with evidence of moderate-to-severe hepatic
inflammation and early stage fibrosis, with 50% overall tumor
necrosis. In the same study, a patient with metastatic rectal
cancer also went on to have a liver resection, and this time
histology revealed residual microspheres, moderate-to-severe
inflammation with no evidence of fibrosis and 80% tumor
necrosis. In addition, the study describes residual micro-
sphere embolization surrounding resected esophageal and
cholangiocarcinoma liver metastases with 80% and 45%
tumor necrosis respectively. 
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Fig. 2 – Top row: Axial T2 fast relaxation fast spin-echo fat-saturated (T2 FRFSE FS) MRI before (far left), 2 months (middle 
left), 4 months (middle right), and 7 months (far right) following the SIRT procedure. Middle row: Early phase T1 LAVA MRI of 
the same axial sections for the same time points. Bottom row: Late phase T1 LAVA MRI of the same. The liver tumors 
initially respond well to therapy at 2 months, are stable at 4 months, before subsequent progression at 7 months. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Another study examined the histology of the nonneopla-
sic liver parenchyma in 7 patients 6-23 months following SIRT
in metastatic colorectal cancer.[3] , hepatocellular carcinoma
[2] , and neuroendocrine tumor [1,23] . Of the 7 tissue sam-
ples, 6 were core biopsies and 1was a wedge resection. Of
the biopsies, 5/6 demonstrated microspheres, typically in the
portal tracts and without significant associated inflamma-
tion. Mild portal vein dilatation was seen in 3/6, mild por-
tal fibrosis in 2/6, and in 1 case a particle was demonstrated
in an artery with associated thrombus. The wedge resection
demonstrated extensive coagulative necrosis of hepatocytes
due to portal vein thrombosis. The study suggests that SIRT
causes little diagnostic pathologic change in the normal liver
surrounding the liver metastasis, and that the microspheres
are generally found in the portal tracts with little inflamma-
tory reaction. 
In the present case report, we present the long-term radio-
logical and histological outcomes post-SIRT in a single patient
with liver metastasis from breast cancer refractory to stan-
dard systemic chemotherapies. Our histological findings are
consistent with previous histology reports and demonstrate
the persistence of the resin microspheres in situ. In this par-ticular isolated case, no surrounding inflammatory response
was demonstrated. 
Summary 
SIRT may have a role for liver-directed therapy in selected
patients with advanced metastatic liver disease, were other
treatment options are limited. We have presented the radio-
logical outcomes and histopathological findings of long-term
retention of microspheres in a breast cancer patient with ex-
tensive liver metastasis treated with SIRT. 
Learning points 
In the treatment of unresectable, chemorefractory metastatic
liver tumors: 
1. The safety of SIRT has been demonstrated in both early
phase and later phase studies, typically in the setting of
colorectal cancer metastasis. 
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Fig. 3 – Histology images obtained using slide scanner at 20 ×magnification. Top: (a) Hematoxylin and eosin stain of liver 
breast metastasis biopsy core demonstrating presence of the characteristic spherical yttrium-90 microspheres within tumor 
set in abundant fibrous stroma. Bottom: (b) A further tumor fragment from the same biopsy core demonstrates further 
tumor set in a smaller amount of fibrous stroma and this time, absence of microspheres. Neither sample demonstrates 
tumor necrosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2. SIRT is a potential treatment modality in the treatment
of liver metastases from breast cancer, where it has been
shown to be well-tolerated in retrospective series. 
3. Postradioembolization syndrome (fatigue, nausea, gas-
trointestinal upset, fever, and cachexia) is commonly seen
post-SIRT and is generally mild and self-limiting; symp-
tomatic management may be required. 
4. Radioembolisation-induced liver disease (jaundice and as-
cites 1-2 months’ postprocedure) is 1 potential complica-
tion post-SIRT. 5. Reports of post-SIRT tumor histology are limited but typi-
cally residual microspheres are demonstrated in the portal
tracts of surrounding liver with little inflammatory change.
6. MRI, CT, or 2-[ 18 F]-fluoro-2-deoxy- d -glucose positron emis-
sion tomography/computed tomography is typically used
to evaluate radiological response at 1-2 months post-SIRT.
7. Several studies have demonstrated that SIRT can signif-
icantly improve hepatic progression-free survival in pa-
tients with liver metastasis from colorectal cancer. 
8. Evaluation of SIRT in Phase 3 studies is on-going, particu-
larly in liver-only or liver-dominant disease. 
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